The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19: A systematic review

Standard

The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19: A systematic review. / Xiao, Ningkun ; Huang, Xinlin; Kang, Xiaotian et al.
In: Medicine, Vol. 102, No. 27, e34105, 07.07.2023.

Research output: Contribution to journal › Review article › peer-review

BibTeX

@article{ef65270c504a47deb17ea12b898742c8,

title = "The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19: A systematic review",

abstract = "Background: Recent trials have highlighted the potential of oral antiviral VV116 in the treatment of patients with mild COVID-19. However, no comprehensive studies have assessed the safety and efficacy of VV116. Therefore, we conducted a systematic review to assess the safety and efficacy of VV116. Methods: A comprehensive search was conducted on PubMed, Scopus, and Google Scholar websites, with a cutoff date of March 23, to identify pertinent studies. Results: The results from the 3 included studies indicated that no serious adverse events were reported in the VV116 experimental groups, which exhibited a 2.57-day faster time to viral shedding than the control group and demonstrated non-inferiority to the nirmatrelvir-ritonavir control group in alleviating major symptoms. Discussion: Collectively, available studies suggest a reliable safety and efficacy profile for VV116. However, the limited number of trials was insufficient for meta-analysis, and the included population consisted of younger individuals with mild and moderate symptoms, not encompassing the elderly who are severely affected by COVID-19. We hope that more studies will be conducted in the future to ensure that VV116 has a more reliable safety and efficacy profile in the clinical setting, especially in severe or critical patients. {\textcopyright} 2023 Lippincott Williams and Wilkins. All rights reserved.",

author = "Ningkun Xiao and Xinlin Huang and Xiaotian Kang and Wanli Zang and Bo Li and Sergey Kiselev",

note = "This research was conducted with financial support from Ural Federal University.",

year = "2023",

month = jul,

day = "7",

doi = "10.1097/MD.0000000000034105",

language = "English",

volume = "102",

journal = "Medicine",

issn = "0025-7974",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "27",

}

RIS

TY - JOUR

T1 - The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19: A systematic review

AU - Xiao, Ningkun

AU - Huang, Xinlin

AU - Kang, Xiaotian

AU - Zang, Wanli

AU - Li, Bo

AU - Kiselev, Sergey

N1 - This research was conducted with financial support from Ural Federal University.

PY - 2023/7/7

Y1 - 2023/7/7

N2 - Background: Recent trials have highlighted the potential of oral antiviral VV116 in the treatment of patients with mild COVID-19. However, no comprehensive studies have assessed the safety and efficacy of VV116. Therefore, we conducted a systematic review to assess the safety and efficacy of VV116. Methods: A comprehensive search was conducted on PubMed, Scopus, and Google Scholar websites, with a cutoff date of March 23, to identify pertinent studies. Results: The results from the 3 included studies indicated that no serious adverse events were reported in the VV116 experimental groups, which exhibited a 2.57-day faster time to viral shedding than the control group and demonstrated non-inferiority to the nirmatrelvir-ritonavir control group in alleviating major symptoms. Discussion: Collectively, available studies suggest a reliable safety and efficacy profile for VV116. However, the limited number of trials was insufficient for meta-analysis, and the included population consisted of younger individuals with mild and moderate symptoms, not encompassing the elderly who are severely affected by COVID-19. We hope that more studies will be conducted in the future to ensure that VV116 has a more reliable safety and efficacy profile in the clinical setting, especially in severe or critical patients. © 2023 Lippincott Williams and Wilkins. All rights reserved.

AB - Background: Recent trials have highlighted the potential of oral antiviral VV116 in the treatment of patients with mild COVID-19. However, no comprehensive studies have assessed the safety and efficacy of VV116. Therefore, we conducted a systematic review to assess the safety and efficacy of VV116. Methods: A comprehensive search was conducted on PubMed, Scopus, and Google Scholar websites, with a cutoff date of March 23, to identify pertinent studies. Results: The results from the 3 included studies indicated that no serious adverse events were reported in the VV116 experimental groups, which exhibited a 2.57-day faster time to viral shedding than the control group and demonstrated non-inferiority to the nirmatrelvir-ritonavir control group in alleviating major symptoms. Discussion: Collectively, available studies suggest a reliable safety and efficacy profile for VV116. However, the limited number of trials was insufficient for meta-analysis, and the included population consisted of younger individuals with mild and moderate symptoms, not encompassing the elderly who are severely affected by COVID-19. We hope that more studies will be conducted in the future to ensure that VV116 has a more reliable safety and efficacy profile in the clinical setting, especially in severe or critical patients. © 2023 Lippincott Williams and Wilkins. All rights reserved.

UR - http://www.scopus.com/inward/record.url?partnerID=8YFLogxK&scp=85164260084

UR - https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=tsmetrics&SrcApp=tsm_test&DestApp=WOS_CPL&DestLinkType=FullRecord&KeyUT=001025647200037

U2 - 10.1097/MD.0000000000034105

DO - 10.1097/MD.0000000000034105

M3 - Review article

VL - 102

JO - Medicine

JF - Medicine

SN - 0025-7974

IS - 27

M1 - e34105

ER -

ID: 41983018